Kathy D Miller, MD
@kathydmillermd.bsky.social
Medical Oncologist, breast cancer researcher, nature lover, mother of two teenagers
Unfortunately the study design doesn’t allow us to evaluate clinical utility of the early switch
Clearly an active drug… but this isn’t the way to use it
Clearly an active drug… but this isn’t the way to use it
August 10, 2025 at 8:55 PM
Unfortunately the study design doesn’t allow us to evaluate clinical utility of the early switch
Clearly an active drug… but this isn’t the way to use it
Clearly an active drug… but this isn’t the way to use it
Nora
When you account for lead time bias, it’s not clear this is even a single
When you account for lead time bias, it’s not clear this is even a single
June 5, 2025 at 12:16 AM
Nora
When you account for lead time bias, it’s not clear this is even a single
When you account for lead time bias, it’s not clear this is even a single
Clearly an active drug but this may not be the best way to use it or to really benefit patients
Discussant Dr DeMichele did a great job explaining the problems with study design and interpretation
Discussant Dr DeMichele did a great job explaining the problems with study design and interpretation
June 1, 2025 at 11:17 PM
Clearly an active drug but this may not be the best way to use it or to really benefit patients
Discussant Dr DeMichele did a great job explaining the problems with study design and interpretation
Discussant Dr DeMichele did a great job explaining the problems with study design and interpretation
Ithenticate works well
May 18, 2025 at 12:14 PM
Ithenticate works well
So thoughtful and personal… way better than the standard coffee mug😀
March 31, 2025 at 11:17 PM
So thoughtful and personal… way better than the standard coffee mug😀
So sorry Wendy. Wishing you both peace
January 19, 2025 at 12:10 PM
So sorry Wendy. Wishing you both peace
Kudos to Dr Krop for. Great balanced discussion. MRD testing has great promise but also brings great potential for harm. Success of any MRD test is inextricably linked to success of our therapeutic interventions. We’re just not there yet.
Bottom line…don’t do it
#SABCS2024
Bottom line…don’t do it
#SABCS2024
December 13, 2024 at 11:36 PM
Kudos to Dr Krop for. Great balanced discussion. MRD testing has great promise but also brings great potential for harm. Success of any MRD test is inextricably linked to success of our therapeutic interventions. We’re just not there yet.
Bottom line…don’t do it
#SABCS2024
Bottom line…don’t do it
#SABCS2024
Hard to get excited or see a future for atezo in breast
Neg results for EFS in GerparDouze, neg adjuvant Impassion 030, no benefit with paclitaxel in MBC
No spin here, time to move in and conclude pembro just makes gut be better in our disease
#SABCS2024
Neg results for EFS in GerparDouze, neg adjuvant Impassion 030, no benefit with paclitaxel in MBC
No spin here, time to move in and conclude pembro just makes gut be better in our disease
#SABCS2024
December 13, 2024 at 5:58 PM
Hard to get excited or see a future for atezo in breast
Neg results for EFS in GerparDouze, neg adjuvant Impassion 030, no benefit with paclitaxel in MBC
No spin here, time to move in and conclude pembro just makes gut be better in our disease
#SABCS2024
Neg results for EFS in GerparDouze, neg adjuvant Impassion 030, no benefit with paclitaxel in MBC
No spin here, time to move in and conclude pembro just makes gut be better in our disease
#SABCS2024
Important message lost here
Hormone inhibition is key if ER positive regardless oh HER2. Many HER2 focused trials exclude/ don’t allow ongoing hormone therapy. Cleopatra for example … if the tumor has both targets we shouldn’t have to choose
Hormone inhibition is key if ER positive regardless oh HER2. Many HER2 focused trials exclude/ don’t allow ongoing hormone therapy. Cleopatra for example … if the tumor has both targets we shouldn’t have to choose
December 12, 2024 at 5:55 PM
Important message lost here
Hormone inhibition is key if ER positive regardless oh HER2. Many HER2 focused trials exclude/ don’t allow ongoing hormone therapy. Cleopatra for example … if the tumor has both targets we shouldn’t have to choose
Hormone inhibition is key if ER positive regardless oh HER2. Many HER2 focused trials exclude/ don’t allow ongoing hormone therapy. Cleopatra for example … if the tumor has both targets we shouldn’t have to choose
No doubt ctDNA informs risk estimates. What we need and still lack is data on outcomes
Specifically do patients live longer if managed with knowledge of the test than without
Specifically do patients live longer if managed with knowledge of the test than without
December 10, 2024 at 10:39 PM
No doubt ctDNA informs risk estimates. What we need and still lack is data on outcomes
Specifically do patients live longer if managed with knowledge of the test than without
Specifically do patients live longer if managed with knowledge of the test than without
No question ctDNA can inform estimates of risk
What we lack and need is data on patient outcomes
Specifically do patients live longer if management decisions are made with knowledge of the test versus not
What we lack and need is data on patient outcomes
Specifically do patients live longer if management decisions are made with knowledge of the test versus not
December 10, 2024 at 9:22 PM
No question ctDNA can inform estimates of risk
What we lack and need is data on patient outcomes
Specifically do patients live longer if management decisions are made with knowledge of the test versus not
What we lack and need is data on patient outcomes
Specifically do patients live longer if management decisions are made with knowledge of the test versus not
Amazing progress powered by basic science and spurred by advocates who demanded better access and engagement
Still remember my time on Osler 8, the aids unit at JHU back in the day
Still remember my time on Osler 8, the aids unit at JHU back in the day
December 10, 2024 at 4:40 PM
Amazing progress powered by basic science and spurred by advocates who demanded better access and engagement
Still remember my time on Osler 8, the aids unit at JHU back in the day
Still remember my time on Osler 8, the aids unit at JHU back in the day
Don
I had read and admired the piece
I was reflecting on the experiences of two recent trans patients, each seen in one of my two clinic locations
One visit started with a patient in tears from the limited options the intake form provided
Sorry my comment didn’t include enough words
I had read and admired the piece
I was reflecting on the experiences of two recent trans patients, each seen in one of my two clinic locations
One visit started with a patient in tears from the limited options the intake form provided
Sorry my comment didn’t include enough words
December 9, 2024 at 11:31 PM
Don
I had read and admired the piece
I was reflecting on the experiences of two recent trans patients, each seen in one of my two clinic locations
One visit started with a patient in tears from the limited options the intake form provided
Sorry my comment didn’t include enough words
I had read and admired the piece
I was reflecting on the experiences of two recent trans patients, each seen in one of my two clinic locations
One visit started with a patient in tears from the limited options the intake form provided
Sorry my comment didn’t include enough words
Personally I have always hated both. We all have things to learn and things we can teach
December 9, 2024 at 6:28 PM
Personally I have always hated both. We all have things to learn and things we can teach
Great practical advice in this piece? When’s the last time you looked at patient intake forms with an eye toward diversity and inclusion?
December 9, 2024 at 6:26 PM
Great practical advice in this piece? When’s the last time you looked at patient intake forms with an eye toward diversity and inclusion?